Zentiva Pharma UK Ltd

Information

Name

Type

Company

Roles

Supplier

Company Size

Large

Company Number

Incorporation Date

Website

Address

12 New Fetter Lane

london
EC4A 1JP
United Kingdom

Suppliers

Unlock the full supplier list, free!

Sign up to unlock the full list of suppliers associated with Zentiva Pharma UK Ltd
Sign up free

Contracts awarded to Zentiva Pharma UK Ltd

The contracts that Zentiva Pharma UK Ltd have been awarded to supply. Click on the contract to view more detailed information and view the full details about the contract won.

Award

Published 1 month ago

NHS National Framework for Transition products commencing 1 October 2024

Project title: NHS National Framework for Transition products commencing 1 October 2024 Offer reference number: CM/TNS/24/5712 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months. Potential periods of call-offs under the framework agreement: CM/TNS/24/5712/01 - Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets Lot 1 CESW: 01/10/2024 to 30/09/2025 (12 months) Lot 2 NWLN: 01/10/2024 to 30/09/2025 (12 months) Lot 3 LSNE: 01/10/2024 to 31/05/2026 (20 months) CM/TNS/24/5712/02 - Imatinib Lot 1 DSW: 01/10/2024 to 30/09/2025 (12 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

£41,320,000 Bids close: 3 months ago
Award

Published 1 month ago

NHS National Framework for Transition products commencing 1 October 2024

Project title: NHS National Framework for Transition products commencing 1 October 2024 Offer reference number: CM/TNS/24/5712 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months. Potential periods of call-offs under the framework agreement: CM/TNS/24/5712/01 - Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets Lot 1 CESW: 01/10/2024 to 30/09/2025 (12 months) Lot 2 NWLN: 01/10/2024 to 30/09/2025 (12 months) Lot 3 LSNE: 01/10/2024 to 31/05/2026 (20 months) CM/TNS/24/5712/02 - Imatinib Lot 1 DSW: 01/10/2024 to 30/09/2025 (12 months) Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England

£13
Award

Published 2 months ago

ENT, Ophthalmology & Skin Medicines/Medical Devices

Supply of ENT, Ophthalmology & Skin Medicines/Medical Devices to NHS Scotland.

£10,838,512
Award

Published 3 months ago

NHS Branded Medicines Tranche Framework for London and South of England

NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024 Offer reference number: CM/PHR/22/5689 CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

£380,950,720 Bids close: 7 months ago
Award

Published 3 months ago

NHS Branded Medicines Tranche Framework for London and South of England

NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024 Offer reference number: CM/PHR/22/5689 CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.

£39
Award

Published 3 months ago

Generic, Branded Generic & Proprietary Medicinal Products - Group 14

Generic, Branded Generic & Proprietary Medicinal Products - Group 14 (5190931)

£10,725,841

Contacts

+44 800854431

Statistics (1 Year)

Contracts Won

Total Won

£51,211,621

Average Win

£17,070,540

Zentiva Pharma UK Ltd

Information

Name

Type

Roles

Company Size

Company Number

Incorporation Date

Website

Address

Suppliers

Contracts awarded to Zentiva Pharma UK Ltd

NHS National Framework for Transition products commencing 1 October 2024

NHS National Framework for Transition products commencing 1 October 2024

ENT, Ophthalmology & Skin Medicines/Medical Devices

NHS Branded Medicines Tranche Framework for London and South of England

NHS Branded Medicines Tranche Framework for London and South of England

Generic, Branded Generic & Proprietary Medicinal Products - Group 14

Contacts

Statistics (1 Year)

Contracts Won

Total Won

Average Win